{"product_id":"handbook-of-contemporary-neuropharmacology-3-volume-set-9780471660538","title":"Handbook of Contemporary Neuropharmacology 3 Volume Set","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWritten at the professional level, the Handbook of Contemporary Neuropharmacology consists of chapters reviewing basic and advanced topics in neuropharmacology. The scope of the Handbook is heavily pre-clinical, covering mostly basic science topics; however, the chapters are organized under a clinical 'umbrella'.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"...an admirable job of bringing together many aspects of neuropharmacology in one place...well worth your while to examine it.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e, September 20, 2007)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface.  \u003cp\u003eContributors.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 1.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: BASIC NEUROPHARMACOLOGY.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1: Soup or Sparks: The History of Drugs and Synapses (\u003ci\u003eWilliam Van der Kloot\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 2: Synaptic Transmission: Intercellular Signaling (\u003ci\u003eJ. David Jentsch and Robert H. Roth\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 3: Synaptic Transmission: Intracellular Signaling (\u003ci\u003eR. Benjamin Free, Lisa A. Hazelwood, Yoon Namkung Michele L. Rankin, Elizabeth B. Rex, and David R. Sibley\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 4: Neuronal Nicotinic Receptors: One Hundred Years of Progress (\u003ci\u003eKenneth J. Kellar and Yingxian Xiao\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 5: Muscarinic Acetylcholine Receptors (\u003ci\u003eJürgen Wess\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 6: Norepinephrine\/Epinephrine (\u003ci\u003eMegan E. Kozisek and David B. Bylund\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 7: Dopaminergic Neurotransmission (\u003ci\u003eJohn A. Schetz and David R. Sibley\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 8: Serotonin Systems (\u003ci\u003eJohn A. Gray and Bryan L. Roth\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 9: Neuropharmacology of Histamine in Brain (\u003ci\u003eRaphae¨l Faucard and Jean-Charles Schwartz\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 10: Ionotropic Glutamate Receptors (\u003ci\u003eDavid Bleakman, Andrew Alt, David Lodge, Daniel T. Monaghan, David E. Jane, and Eric S. Nisenbaum\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 11: Metabotropic Glutamate Receptors (\u003ci\u003eJames A. Monn, Michael P. Johnson, and Darryle D. Schoepp\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 12: Pharmacology of the GABAA Receptor (\u003ci\u003eDmytro Berezhnoy, Maria C. Gravielle, and David H. Farb\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 13: Metabotropic GABA Receptors (\u003ci\u003eMartin Gassmann and Bernhard Bettler\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 14: Voltage-Gated Ion Channels (\u003ci\u003eAlex Fay, Patrick C. G. Haddick, and Lily Yeh Jan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 15: Neuropeptides (\u003ci\u003eFleur L. Strand\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 16: Neurotransmitter Transporters (\u003ci\u003eJia Hu, Katherine Leitzell, Dan Wang, and Michael W. Quick\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 17: Gaseous Signaling: Nitric Oxide and Carbon Monoxide as Messenger Molecules (\u003ci\u003eKenny K. K. Chung, Valina L. Dawson, and Ted M. Dawson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: MOOD DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 18: Neurobiology and Treatment of Depression (\u003ci\u003eAlexander Neumeister, Dennis S. Charney, Gerard Sanacora, and John H. Krystal\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 19: Neurotrophic Factors in Etiology and Treatment of Mood Disorders (\u003ci\u003eRonald S. Duman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 20: Antidepressant Treatment and Hippocampal Neurogenesis: Monoamine and Stress Hypotheses of Depression Converge (\u003ci\u003eAlex Dranovsky and René Hen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 21: Neuroendocrine Abnormalities in Women with Depression Linked to the Reproductive Cycle (\u003ci\u003eBarbara L. Parry, Charles J. Meliska, L. Fernando Martinez, Eva L. Maurer, Ana M. Lopez, and Diane L. Sorenson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 22: Neurobiology and Pharmacotherapy of Bipolar Disorder (\u003ci\u003eR. H. Belmaker, G. Agam, and R. H. Lenox\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eCumulative Index.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 2.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: ANXIETY AND STRESS DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1: Neurobiology of Anxiety (\u003ci\u003eMiklos Toth and Bojana Zupan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 2: Pharmacotherapy of Anxiety (\u003ci\u003eJon R. Nash and David J. Nutt\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 3: Benzodiazepines (\u003ci\u003eHartmut Lu¨ddens and Esa R. Korpi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 4: Neuroactive Steroids in Anxiety and Stress (\u003ci\u003eDeborah A. Finn and Robert H. Purdy\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 5: Emerging Anxiolytics: Corticotropin-Releasing Factor Receptor Antagonists (\u003ci\u003eDimitri E. Grigoriadis and Samuel R. J. Hoare\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 6: Neurobiology and Pharmacotherapy of Obsessive-Compulsive Disorder (\u003ci\u003eJudith L. Rapoport and Gale Inoff-Germain\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: SCHIZOPHRENIA AND PSYCHOSIS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 7: Phenomenology and Clinical Science of Schizophrenia (\u003ci\u003eSubroto Ghose and Carol Tamminga\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 8: Dopamine and Glutamate Hypotheses of Schizophrenia (\u003ci\u003eBita Moghaddam and Houman Homayoun\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 9: Molecular Genetics of Schizophrenia (\u003ci\u003eLiam Carroll, Michael C. O’Donovan, and Michael J. Owen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 10: Postmortem Brain Studies: Focus on Susceptibility Genes in Schizophrenia (\u003ci\u003eShiny V. Mathew, Shruti N. Mitkus, Barbara K. Lipska, Thomas M. Hyde, and Joel E. Kleinman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 11: Pharmacotherapy of Schizophrenia (\u003ci\u003eZafar Sharif, Seiya Miyamoto, and Jeffrey A. Lieberman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 12: Atypical Antipsychotic Drugs: Mechanism of Action (\u003ci\u003eHerbert Y. Meltzer\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: SUBSTANCE ABUSE AND ADDICTIVE DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 13: Introduction to Addictive Disorders: Implications for Pharmacotherapies (\u003ci\u003eMary Jeanne Kreek\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 14: Dopaminergic and GABAergic Regulation of Alcohol-Motivated Behaviors: Novel Neuroanatomical Substrates (\u003ci\u003eHarry L. June and William J. A. Eiler II\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 15: Nicotine (\u003ci\u003eAugust R. Buchhalter, Reginald V. Fant, and Jack E. Henningfield\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 16: Psychostimulants (\u003ci\u003eLeonard L. Howell and Heather L. Kimmel\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 17: MDMA and Other \"Club Drugs\" (\u003ci\u003eM. Isabel Colado, Esther O’Shea, and A. Richard Green\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 18: Marijuana: Pharmacology and Interaction with the Endocannabinoid System (\u003ci\u003eJenny L. Wiley and Billy R. Martin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 19: Opiates and Addiction (\u003ci\u003eFrank J. Vocci\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: PAIN.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 20: Neuronal Pathways for Pain Processing (\u003ci\u003eGavril W. Pasternak and Yahong Zhang\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 21: Vanilloid Receptor Pathways (\u003ci\u003eMakoto Tominaga\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 22: Opioid Receptors (\u003ci\u003eGavril W. Pasternak\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 23: Advent of A New Generation of Antimigraine Medications (\u003ci\u003eAna Recober and Andrew F. Russo\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eCumulative Index.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 3.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: SLEEP AND AROUSAL.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1: Function and Pharmacology of Circadian Clocks (\u003ci\u003eGabriella B. Lundkvist and Gene D. Block\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 2: Melatonin Receptors in Central Nervous System (\u003ci\u003eMargarita L. Dubocovich\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 3: Narcolepsy: Neuropharmacological Aspects (\u003ci\u003eSeiji Nishino\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 4: Hypocretin\/Orexin System (\u003ci\u003eJ. Gregor Sutcliffe and Luis de Lecea\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 5: Prokineticins: New Pair of Regulatory Peptides (\u003ci\u003eMichelle Y. Cheng and Qun-Yong Zhou\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 6: Sedatives and Hypnotics (\u003ci\u003eKeith A. Wafford and Paul J. Whiting\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: DEVELOPMENT AND DEVELOPMENTAL DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 7: Regulation of Adult Neurogenesis (\u003ci\u003eHeather A. Cameron\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 8: Neurotrophic Factors (\u003ci\u003eFranz F. Hefti and Patricia A. Walicke\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 9: Neurotrophins and Their Receptors (\u003ci\u003eMark Bothwell\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 10: Tourette’s Syndrome and Pharmacotherapy (\u003ci\u003ePieter Joost van Wattum and James F. Leckman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 11: Neuropharmacology of Attention-Deficit\/Hyperactivity Disorder (\u003ci\u003ePaul E. A. Glaser, F. Xavier Castellanos, and Daniel S. Margulies\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 12: Psychopharmacology of Autism Spectrum Disorders (\u003ci\u003eAdriana Di Martino, Steven G. Dickstein, Alessandro Zuddas, and F. Xavier Castellanos\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: NEURODEGENERATIVE AND SEIZURE DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 13: Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy (\u003ci\u003eMichael J. O’Neill, David Lodge, and James McCulloch\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 14: Epilepsy: Mechanisms of Drug Action and Clinical Treatment (\u003ci\u003eWilliam H. Theodore and Michael A. Rogawski\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 15: Pharmacotherapy for Traumatic Brain Injury (\u003ci\u003eDonald G. Stein and Stuart W. Hoffman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 16: Dementia and Pharmacotherapy: Memory Drugs (\u003ci\u003eJerry J. Buccafusco\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 17: Pharmacotherapy and Treatment of Parkinson’s Disease (\u003ci\u003eWing Lok Au and Donald B. Calne\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 18: Parkinson’s Disease: Genetics and Pathogenesis (\u003ci\u003eClaudia M. Testa\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 19: Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases (\u003ci\u003eRichard Nass and Charles D. Nichols\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: NEUROIMMUNOLOGY.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 20: Myelin Lipids and Proteins: Structure, Function, and Roles in Neurological Disorders (\u003ci\u003eRichard H. Quarles\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 21: Pharmacology of Inflammation (\u003ci\u003eCarmen Espejo and Roland Martin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 22: Pharmacological Treatment of Multiple Sclerosis (\u003ci\u003eB. Mark Keegan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 23: Novel Therapies for Multiple Sclerosis (\u003ci\u003eMartin S. Weber and Scott S. Zamvil\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 24: Neuropharmacology of HIV\/AIDS (\u003ci\u003eSidney A. Houff and Eugene O. Major\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART V: EATING AND METABOLIC DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 25: Leptin: A Metabolic Perspective (\u003ci\u003eDawn M. Penn, Cherie R. Rooks, and Ruth B. S. Harris\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 26: Ghrelin: Structural and Functional Properties (\u003ci\u003eBirgitte Holst, Kristoffer Egerod, and Thue W. Schwartz\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 27: Mechanisms Controlling Adipose Tissue Metabolism by the Sympathetic Nervous System: Anatomical and Molecular Aspects (\u003ci\u003eSheila Collins, Renato H. Migliorini, and Timothy J. Bartness\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 28: Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives (\u003ci\u003eYuguang Shi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eCumulative Index.\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":53733848875351,"sku":"9780471660538","price":858.56,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780471660538.jpg?v=1782119367","url":"https:\/\/bookcurl.com\/products\/handbook-of-contemporary-neuropharmacology-3-volume-set-9780471660538","provider":"Book Curl","version":"1.0","type":"link"}